孟鲁司特钠联合盐酸西替利嗪及布地奈德雾化治疗小儿咳嗽变异性哮喘的临床效果

Clinical Effect of Montelukast Sodium Combined with Cetirizine Hydrochloride and Budesonide Atomization in the Treatment of Cough Variant Asthma in Children

目的分析孟鲁司特钠联合盐酸西替利嗪及布地奈德在小儿咳嗽变异性哮喘(CVA)患儿中的应用效果。方法选择2020年11月—2022年11月于临沂高新医院门诊就诊的80例CVA患儿为研究对象,按随机数字表法分为两组。对照组(n=40)采用布地奈德雾化吸入联合盐酸西替利嗪口服治疗,观察组(n=40)在此基础上采用孟鲁司特钠治疗,均持续治疗1周。对比两组患者的治疗总有效率、症状消失时间、免疫功能及不良反应发生情况。结果观察组的治疗总有效率为97.50%,高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗后,观察组的CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)水平分别为(40.26±4.03)%、(58.48±5.05)%、(1.64±0.52),均高于对照组的(36.29±3.87)%、(51.17±4.67)%、(1.37±0.43),CD8^(+)水平为(20.04±3.07)%,低于对照组的(26.22±3.25)%,组间差异有统计学意义(P<0.05)。治疗后,观察组的憋喘、咳嗽、哮鸣音、肺湿啰音消失时间分别为(2.83±0.63)d、(6.25±1.26)d、(5.02±1.04)d、(5.27±1.05)d,均短于对照组的(3.48±0.84)d、(7.27±1.65)d、(5.76±1.47)d、(6.55±1.52)d,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论孟鲁司特钠联合盐酸西替利嗪及布地奈德治疗CVA的效果确切,能加快临床症状缓解,改善患儿机体免疫功能,且安全性高。

Objective To analyze the effect of montelukast sodium combined with cetirizine hydrochloride and budesonide in children with cough variant asthma(CVA).Methods 80 children with CVA who received outpatient treatment in Linyi High-Tech Hospital from November 2020 to November 2022 were selected as the research objects and were divided into two groups according to random number table method.The control group(n=40)received budesonide aerosol inhalation combined with cetirizine hydrochloride orally,and the observation group(n=40)received montelukast sodium on the basis of the treatment.Both groups were treated for 1 week.The total effective rate,duration of symptom disappearance,immune function and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.50%,which was higher than 80.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD4^(+),CD3^(+)and CD4^(+)/CD8^(+)in the observation group were(40.26±4.03)%,(58.48±5.05)%and(1.64±0.52),respectively,which were higher than(36.29±3.87)%,(51.17±4.67)%and(1.37±0.43)in the control group,while the CD8^(+)level was(20.04±3.07)%,lower than(26.22±3.25)%in the control group,the differences between the groups were statistically significant(P<0.05).After treatment,the disappearance time of dyspnea,cough,wheezing and pulmonary moist rale in the observation group was(2.83±0.63)d,(6.25±1.26)d,(5.02±1.04)d,(5.27±1.05)d,respectively,which were shorter than(3.48±0.84)d,(7.27±1.65)d,(5.76±1.47)d and(6.55±1.52)d in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Montelukast sodium combined with cetirizine hydrochloride and budesonide is effective in the treatment of CVA,which can accelerate the remission of clinical symptoms and improve the immune function of children with high safety.